Tempus

Boehringer Ingelheim will have access to Tempus' de-identified database to use patient data for biomarker development and target discovery efforts.

The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

The collaboration, under which Tempus will collect data licensing and model development fees, will leverage its repository of de-identified multimodal patient data.